DS-5272

DS-5272 is a potent, orally active small molecule inhibitor that targets the interaction between p53 and MDM2. By inhibiting this protein-protein interaction, DS-5272 reactivates the tumor suppressor function of p53, leading to cell cycle arrest and apoptosis in cancer cells with wild-type TP53. The compound features a dihydroimidazothiazole scaffold optimized for potency and safety, showing strong antitumor efficacy in preclinical models such as SJSA-1 xenografts and clear cell ovarian carcinoma models. It has demonstrated antiangiogenic effects, reduction of tumor burden, decreased vascular endothelial growth factor (VEGF) levels, and improved survival in animal studies. Developed by Daiichi Sankyo as a molecularly targeted therapy for cancers with functional p53 pathways[1][3][4][5][6].

Other names

DS 5272DS5272DS-5272